The safety and effectiveness of Fabrazyme have been established in pediatric individuals based on adequate and well-controlled studies in adults, a single-arm, open-label study in 16 pediatric individuals with Fabry disease aged 8 to 16 years, and additional data in 24 individuals with Fabry disease aged 2 to 7 years.